An analyst from Chardan, Keay Nakae, has begun covering Monopar Therapeutics (MNPR, Financial), giving it a Buy rating along with a price target of $60. This optimistic outlook is based on the promising potential of Monopar's advanced clinical asset for treating Wilson disease, as well as its early-stage radiopharmaceutical pipeline. The company's CEO and co-founder, Dr. Chandler Robinson, brings substantial experience in the development of ALXN1840, bolstering investor confidence. This insight suggests a strong capability for progress in Monopar's innovative endeavors.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 3 analysts, the average target price for Monopar Therapeutics Inc (MNPR, Financial) is $58.00 with a high estimate of $76.00 and a low estimate of $40.00. The average target implies an upside of 77.15% from the current price of $32.74. More detailed estimate data can be found on the Monopar Therapeutics Inc (MNPR) Forecast page.
Based on the consensus recommendation from 4 brokerage firms, Monopar Therapeutics Inc's (MNPR, Financial) average brokerage recommendation is currently 2.3, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
